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Paraganglioma (PGL) is an extra-adrenal chromaffin 
cell tumour. A sympathetic or functioning PGL (sPGL) 
is usually located in the thoracic, abdominal, and pelvic 
regions whereas a parasympathetic or non-functioning 
PGL is usually seen in the head and neck area. The 
organ of Zuckerkandl (OZ) comprises para-aortic para-
ganglia located between the level of inferior mesenteric 
artery and the aortic bifurcation, and this area is the 
most common site of abdominal PGL [1]. Strong ge-
netic association with succinate dehydrogenase (SDHx) 
subunits, particularly SDHB and SDHD, has previously 
been described [2].
The FH gene, a tumour suppressor gene located on 
chromosome 1q43, encodes fumarate hydratase, an im-
mediate downstream of the SDH enzyme in the Krebs 
cycle. Its inactivating mutations predispose to heredi-
tary leiomyomatosis and renal cell carcinoma (HLRCC; 
OMIM # 150800) or Reed’s syndrome and have recently 
been identified in pheochromocytoma/paraganglioma 
(PCC/PGL). Herein, we report a case of functioning 
OZ-PGL without the HLRCC features that carry the 
FH gene mutation. 
A 33-year-old woman presented in 2009 with severe 
hypertension with orthostatic hypotension and a su-
prapubic mass. A functioning OZ-PGL was diagnosed 
by an elevated 24-hour urine metanephrine (361.39 µg; 
normal 52–341 µg) and 24-hour urine normetanephrine 
(810.29 µg; normal 88–444 µg). The patient subsequently 
underwent an uneventful tumour removal [3]. A ge-
netic study was negative for the mutation in the classic 
PCC/PGL susceptibility genes (VHL, RET, SDHB, SDHC, 
and SDHD). There was no evidence of relapse during 
follow-up visits. Ten years later, hypertension recurred 
and corresponded with her abnormal hormonal re-
sults: plasma metanephrine 93.41 pg/mL (0–96.64) and 
normetanephrine 509.35 pg/mL (0–163.05). A com-
puterised tomography (CT) revealed a new lesion of 
the OZ-PGL, located slightly more superior than the 
previous one (Fig. 1). Additionally, 68Ga-DOTATATE 
positron emission tomography/computed tomography 
(PET/CT) scan did not show evidence of metastasis. His-
topathological findings confirmed the diagnosis of PGL 
with a GAPP score of 3 (Fig. 2). The next-generation 
sequencing (NGS) and Sanger confirmatory showed 
a germline FH mutation, c.817G>A on exon 6; resulting 
in an alanine to threonine amino acid substitution in 
the conserved region of FH protein at the position 273, 
p.Ala273Thr. This de novo mutation was predicted “likely 
pathogenic” in accordance with the ACMG/AMP 2015 
guideline because it is not present in either our in-house 
database of 4332 unrelated Thai exome alleles or her un-
affected parents. The patient had no evidence of relapse 
during two-year follow-up periods, also without any 
clinical or radiological feature suggestive of HLRCC, 
cutaneous/uterine leiomyoma, and kidney cancer. 
PCC/PGL is currently described as a tumour with 
the highest hereditability with at least one-third of 
the patients having a germline mutation. Moreover, 
several novel genes have been discovered with the 
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Our study confirms an association of the FH gene 
and PCC/PGL, particularly in the sPGL group, and rec-
ommends that the FH gene be included in the genetic 
testing panel. 
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implementation of NGS technique. With recommenda-
tions for genetic testing in all PCC/PGL patients, par-
ticular phenotypes including syndromic presentations, 
extra-adrenal site or PGL, bilateral or multiple lesions, 
younger age, and malignancy are proposed as a high 
prevalence of genetic determinism [4]. PGL is strongly 
associated with pseudohypoxia-driven genes includ-
ing SDH- and VHL/EPAS1-related genes. In this report 
we demonstrated a case of OZ-PGL carrying FH gene 
mutation, a member of SDH-related genes. 
At least 150 cases of OZ-PGL have been reported, 
of which 70% present as functioning with sympathetic 
overactivity, particularly with norepinephrine predomi-
nance as described in our patient. A non-functioning 
tumour can be presented with abdominal pain or a pal-
pable mass. While about 40% of sPGL carries a germline 
mutation, up to 70% of OZ-PGL has been associated 
with SDHB and SDHD [1,2]. Because of its robust as-
sociation with SDHB, its prevalence of malignancy is 
estimated to be at least 40%, and about 10% of the pa-
tients already had metastasis at the time of diagnosis [1].
Clinical features of the FH-associated PCC/PGL are 
not largely described because it accounts for only 1% of 
the genetically proven PCC/PGL [4]. Age at diagnosis 
ranges from 6 to 70 years [5]. About 40% of the patients 
have metastatic disease. Most mutations are missense and 
scattered throughout the gene. Given the common onco-
metabolic pathway of SDH and FH, phenotypic overlap 
of both gene-related disorders in PCC/PGL is noted. It 
remains unclear whether individuals with FH-related 
PCC/PGL are at high risk of developing other features 
of HLRCC; however, the FH mutations in PCC/PGL and 
HLRCC are in different regions of the gene.
Figure 2. The histology of OZ is shown. Nest of neoplastic 
cell is surrounded by sustentacular cells (black arrow). The 
tumour cells possess mildly pleomorphic round to ovoid nuclei, 
granular chromatin, and basophilic cytoplasm; GAPP score of 3. 
(Haematoxylin-eosin; ×100)
Figure 1. CT scan of the whole abdomen (a) arterial phase, axial 
view and (B) venous phase, sagittal view, shows multiple well-
defined heterogeneous enhancing masses along bilateral para-aortic 
regions, causing anterior displacement of the third part of the 
duodenum (white arrow)
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